INTRODUCTION
Multiple myeloma is a B-cell malignancy characterized by the clonal expansion of tumoral plasma cells in the bone marrow. This accumulation of malignant cells synthesizing immunoglobulins results in hyperproteinemia, renal dysfunctions, bone lesions, and immunodeficiency (1) . This pathology, which accounts for 2% of all cancer deaths per year in occidental countries, remains largely incurable despite novel therapeutic approaches involving the targeting of both multiple myeloma cells and bone marrow environment (2) .
Selective estrogen receptor modulators (SERM), also called antiestrogens, may provide a new strategy in myeloma therapy. Indeed, the presence of estrogen receptor (ER) in various multiple myeloma cells has been suspected for some time (3) and both a and h isotypes have been detected in some multiple myeloma primary cells and cell lines (4, 5) . Moreover, it has been reported that tamoxifen and, to a lesser extent, toremifen inhibit multiple myeloma cell proliferation and in rare cases induce multiple myeloma cell apoptosis (4, 5) . Tamoxifen is widely used in the treatment and prevention of breast cancer where it acts by impairing the estradiol-induced mitogenic activity through binding to ER (6) . 4-Hydroxytamoxifen (4-OHT), the active metabolite of tamoxifen, is a nonsteroidal SERM able to bind ER and to convert it in an inactive form (7) . In the well-studied model of breast cancer, it has been shown that tamoxifen and 4-OHT compete with 17h-estradiol (E2) to inhibit ER-mediated transcription of genes necessary for the proliferation of mammary tumor cells (8) .
Moreover, tamoxifen and 4-OHT are also able to induce apoptosis through an ER-dependent mechanism. ER-independent pathways eliciting apoptosis have also been described but the detailed molecular mechanisms of the latter effects are poorly understood. The addition of tamoxifen or 4-OHT to breast cancer cell lines in culture elicits the activation of effector caspases (9, 10) . In breast cancer cells and in HeLa cells constitutively expressing ER, tamoxifen-or 4-OHT-induced apoptosis recruits the p38 mitogen-activated protein kinase (MAPK) or the c-jun NH 2 -terminal kinase-1 (JNK) signaling pathways (10, 11) .
These observations prompted us to study the effects of 4-OHT on multiple myeloma cells. We have analyzed its in vitro effects on the proliferation and survival of six bona fide myeloma cell lines. We report here that the 4-OHT reduces cell proliferation of ER-expressing multiple myeloma cell lines by two mechanisms: a block in the G 1 phase of the cell cycle and the induction of apoptosis. The induction of apoptosis requires the mitochondrial intrinsic pathway but not the death receptor Fas/FasL pathway nor modifications of signaling pathways known to be essential for multiple myeloma cells survival: phosphatidylinositol 3-kinase/AKT (12, 13) , p70S6K (S6K; ref. 13) , and Janus-activated kinase/ signal transducer and activator of transcription-3 (STAT3; ref. 14) . The G 1 arrest is accompanied by the up-regulation of p27 Kip1 ) and Calbiochem (Darmstadt, Germany), respectively. SB stock solutions were prepared in DMSO at 10 mmol/L and stock E2 and 4-OHT solutions at 10 mmol/L in absolute ethanol. Cells were treated with freshly prepared solutions. For E2, 4-OHT, or SB treatments, ethanol or DMSO vehicle controls were added at the same concentration. Antibodies raised against the following phosphorylated proteins: anti-P-AKT(Ser473), anti-P-STAT3, anti-P-extracellular signal-regulated kinase (ERK), anti-P-S6K, and anti-P-JNK as well as anti-ERK and anti-JNK antibodies, were purchased from Cell Signaling, Inc. (Beverly, MA); antip27 Kip1 , anti-S6K, anti-AKT, anti-Mcl-1, and anti-h-tubulin antibodies were from Santa Cruz (Santa Cruz Biotechnologies, Santa Cruz, CA); anti-Bim antibody was from R&D Systems (R&D Systems Europe, Lille, France); and anti-STAT3 antibody was from PharMingen (BD Biosciences Europe, Erembodegen, Belgium). A monoclonal antibody specific for ERa (D12, Tebu-bio, Le Perray en Yvelines, France) and an antibody specific for ERh (a gift from Dr. J.C. Faye) were used for receptors detection.
Cell Cultures, Treatments, and Cell Proliferation Determination. LP-1, OPM-2, NCI-H929, RPMI 8226, U266, and Karpas 620 multiple myeloma cell lines have been described previously (15) . Cells were maintained in RPMI 1640 supplemented with 10% heat-inactivated FCS, 100 units/ mL penicillin, 100 Ag/mL streptomycin, and 2 mmol/L Lglutamine. In experiments with E2 or 4-OHT, cells were cultured in phenol red -free RPMI 1640 supplemented with charcoal-treated inactivated FCS to eliminate estrogen agonistic or antiagonistic activities. For cell proliferation and viability studies, exponentially growing 2 Â 10 5 cells were seeded into six-well plates, in triplicate, in medium containing either ethanol (vehicle) or various concentrations of 4-OHT. Viable cells, excluding trypan blue, were counted in a hemocytometer at different time intervals. Normal B-lymphocytes were isolated from a spleen (after the informed consent of patient). Cells were purified through Ficoll-Hypaque gradient then cultured in complete RPMI 1640 containing pokeweed mitogen (5 Ag/mL) and in vitro activated 2 hours before antiestrogen treatment.
Cell Viability Determination [2,3- 6 . Mitochondrial retention of DiOC 6 was measured by gating propidium iodide -negative viable cells. Acquisition of events (10,000 gated) and analysis were achieved using the CellQuest software.
Caspase Activity Determination. Caspase activation was determined using caspase-3 and caspase-9 colorimetric assay kits as recommended by the manufacturer (R&D Systems). Briefly, 300 Ag of whole cell lysates (bicinchoninic acid protein assay, Pierce Biotechnology, Inc., Rockford, IL) were incubated for 2 hours at 37jC with 5 AL of 4 mmol/L LEHD-pNA substrate (for caspase-9) or 5 AL of 4 mmol/L DEVD-pNA substrate (for caspase-3) in triplicate. Absorbance of the samples was read at 405 nm and specific absorbance was deduced from background controls (reactions with no substrate). Changes in caspase activity were deduced from the comparison of vehicle-treated and 4-OHT-treated cells.
Transfection of Karpas 620 Cell Line. Transient transfections of Karpas 620 cells were done by electroporation (250 V, 950 AF, GenePulser II, Bio-Rad, Marnes la Coquette, France). Cells were washed, seeded at 10 7 cells in 400 AL of phenol red/ serum-free medium for 2 hours at 37jC, submitted to electrical field, and cultured in complete medium (with charcoal-treated FCS) for 48 hours. Cells were treated with various concentrations of 4-OHT or vehicle and 2,3-bis[2-methoxy-4-nitro-5-sulfophenyl]-2H-tetrazolium-5-carboxanilide inner salt (XTT) assays were done as described. Plasmids expressing ERa and ERh cDNAs were obtained from P. Chambon and B. Haendler, respectively.
Western Blots. NP40 lysates were obtained by resuspending the cells in the following buffer: 1% NP40, 50 mmol/L Tris (pH 7.5), 10% glycerol, 150 mmol/L NaCl, 1 mmol/L EDTA, 100 Amol/L Na 3 VO 4 , 0.5 mmol/L phenylmethylsulfonyl fluoride, and a cocktail of protease inhibitors (Roche Diagnostics). For the preparation of nuclear extracts, cells were first incubated with a buffer containing 10 mmol/L HEPES (pH 7.6), 0.1% NP40, 0.1 mmol/L EDTA, and protease inhibitors as before. Lysates were centrifuged at 12,000 Â g, 4jC for 15 minutes. Pellets were then incubated in radioimmunoprecipitation assay buffer [10 mmol/L Tris (pH 7.5), 150 mmol/L NaCl, 1% NP40, 0.1% SDS, 1% deoxycholic acid, protease inhibitors] for 30 minutes on ice and centrifuged at 15,000 Â g, 4jC for 15 minutes. For ER detection, total cell extracts were prepared by addition of lysis buffer [50 mmol/L HEPES (pH 7.5), 150 mmol/L NaCl, 10% glycerol, 1% Triton X-100, 1.5 mmol/L MgCl 2 , 1 mmol/L EDTA, protease inhibitors]. Cells were lysed for 30 minutes at 4jC followed by 10-minute boiling in Laemmli sample buffer. Proteins (15-100 Ag) were separated by electrophoresis on SDS/PAGE and blotted onto cellulose membranes (Hybond-C super, Amersham Biosciences, Les Ulis, France). Membranes were immunoblotted with the indicated antibodies, then exposed after incubation with the enhanced chemiluminescence Western blotting detection reagent (SuperSignal West Pico Chemiluminescent Substrate, Pierce, Perbio Science France, Brebières). Densitometric analyses were realized with a FluorSImager (Bio-Rad) using the QuantityOne software (Bio-Rad).
Statistical Analysis. The Student t test was used to determine the significance of differences between two experimental groups. Mean of triplicates was analyzed by a two-sided test and P <0.05 was considered significant.
RESULTS
Treatment with 4-Hydroxytamoxifen Reduced Multiple Myeloma Cell Proliferation. We have previously reported that treatment with 4-OHT inhibited the proliferation of three multiple myeloma cell lines, LP-1, NCI-H929, and U266, in a dose-and time-dependent fashion (17) . In the same experimental conditions, 4-OHT had no effect on proliferation of Karpas 620 multiple myeloma cell line (17) . We now extend these observations to two other lines: RPMI 8226 was sensitive to 4-OHT treatment whereas OPM-2 showed no dose response (data not shown and see below).
Inhibition of Multiple Myeloma Cell Proliferation Was due to G 1 Arrest and Apoptosis Induction. To elucidate the mechanisms of multiple myeloma cell inhibition of proliferation, we did cell cycle analysis after propidium iodide -staining and subsequent flow cytometry sorting. 4-OHT-sensitive cells were treated with the same antiestrogen concentrations, 1, 5 and 10 Amol/L, for 48 hours. As an indicator of 4-OHT toxicity, we tested under the same conditions the response of normal mature B-lymphocytes isolated from human spleen and stimulated in vitro with pokeweed mitogen. As depicted in Fig. 1A , 4-OHT treatment induced a G 1 arrest in the four responsive cell lines but at different concentrations. RPMI 8226 cells were blocked after 1 Amol/L 4-OHT treatment (+7%), LP-1 and U266 cells were blocked after 5 Amol/L 4-OHT treatment (+13% and +11%, respectively), whereas NCI-H929 cells were more resistant (+7% for 10 Amol/L 4-OHT). The appearance of a sub-G 1 cells population indicated that multiple myeloma cells underwent apoptosis, again with varying sensitivities. After 10 Amol/L 4-OHT treatment, a high fraction of NCI-H929 and RPMI 8226 cells (+20% and +17%, respectively) and a low fraction of LP-1 and U266 (+7% and +8%, respectively) cells were apoptotic. These results indicate that 4-OHT induces a cell cycle block and triggers apoptosis in multiple myeloma cells. OPM-2 cells were assayed under the same experimental conditions. 4-OHT treatment did not modify the percentage of OPM-2 cells within the G 0 /G 1 and sub-G 1 fractions, confirming their resistance to SERMs (data not shown). Similarly, 4-OHT had no effects on normal mitogen-stimulated B-cells. Indeed, when normal Blymphocytes were exposed to 5 or 10 Amol/L 4-OHT for 48 hours, no major effects on cell cycle distribution were evident and apoptosis was not triggered ( Table 1 ). The examination of sensitivity towards G 1 arrest or apoptosis of each cell line indicates that the two events are independent. Moreover, the sensitivity of multiple myeloma cells to 4-OHT-induced apoptosis was unrelated to the percentage of cells in S phase. The two cell lines possessing the highest percentage of cells in S phase, RPMI 8226 and LP-1 (46% and 43%; Fig. 1A ), did not display the highest percentage of sub-G 1 (23% and 10%) after SERM treatment. The apoptotic nature of cell death after 4-OHT treatment was confirmed by microscopic morphologic examination following 4V ,6-diamidino-2-phenylindole staining (data not shown) and by the quantitation of downstream caspase-3 activity (Fig. 1B) . Caspase-3 is believed to be the major effector (or executioner) caspase and functions downstream of all apoptosis pathways (18) . Activation of caspase-3 was observed in the four 4-OHT-responsive cells, in good agreement with the cell cycle results.
The Response of Multiple Myeloma Cells to 4-Hydroxytamoxifen Is Dependent on Estrogen Receptor Expression. We next determined if the 4-OHT inhibitory effect on multiple myeloma cell proliferation requires the presence of ER (a or h). Expression of both ER isotypes in multiple myeloma cell lines was evaluated by immunoblotting ( Fig. 2A) (4) . Karpas 620 cells did not express any isotype of ER and did not respond to 4-OHT treatment. This suggests that ER is necessary for the cellular response to 4-OHT. In order to verify the functionality of ER expressed on multiple myeloma cells, they were treated with 25 Amol/L E2 for 72 hours and XTT assays were done. As shown in Fig. 2B, U266 , NCI-H929, RPMI 8226, and LP-1 cells showed a decrease in cell viability. By contrast, OPM-2, although expressing both isotypes, did not show any response to E2 treatment, suggesting that in those cells ERs are not functional. Together with previous results, which indicated that OPM-2 cells were resistant to 4-OHT, we propose that the biological effects elicited by 4-OHT require functional ER molecules. To verify this hypothesis, we introduced ERa or 10 Amol/L 4-OHT for 48 hours. As shown in Fig. 3A, 92% to 99% of LP-1, RPMI 8226, and U266 cells expressed Fas, whereas NCI-H929 cells did not. No modifications of the percentage of Fas-positive cells or of mean fluorescent intensity were detected after SERM treatment (Fig. 3A, right) .
To investigate whether or not a mitochondrial-dependent process is involved in the 4-OHT-induced apoptosis, multiple myeloma cells were treated with 10 Amol/L 4-OHT or with vehicle for 24 or 36 hours and costained with propidium iodide and the fluorescent DiOC 6 . As presented in Fig. 3B for RPMI 8226 and U266 cells, mitochondria of vehicle-treated propidium iodide -negative cells displayed a high DiOC 6 retention (74.9% and 88.7%, respectively). By contrast, mitochondria of 4-OHT-treated propidium iodide -negative cells exhibited a decrease of DiOC 6 retention (À29.1% for RPMI 8226 and À15.2% for U266). Our results indicate that 4-OHT causes the disruption of DW m , a reflection of the activation of the intrinsic apoptotic mitochondrial pathway. Caspase-9 is an initiator caspase within the mitochondrial death pathway (18) . In order to detect activation of caspase-9 subsequent to the mitochondrial membrane permeabilization, we analyzed the activity of whole cell extracts on the caspase-9 substrate, LEDH-pNA. As depicted in Fig. 3C , in the three cell lines studied, 4-OHT treatment led to the activation of caspase-9.
Alterations of Survival Pathways Are Not Associated with 4-Hydroxytamoxifen-Mediated Apoptosis. Regulation of multiple myeloma cell survival or proliferation is dependent on different signal transduction pathways such as MAPK, phosphatidylinositol 3-kinase/AKT, S6K, and STAT3 pathways. Some of these pathways are constitutively active in multiple myeloma cells (10 -12). We next analyzed a possible alteration of these pathways following the treatment of multiple myeloma cells with 4-OHT. Extracts prepared from cells treated with various concentrations of 4-OHT (1-10 Amol/L) for 48 hours were analyzed by immunoblotting with antiphosphospecific antibodies raised against signaling molecules. Results obtained with 5 Amol/L 4-OHT are presented in Fig. 4A ; the levels of signaling molecules analyzed were similar following treatment with 10 Amol/L 4-OHT (data not shown). Phosphorylation of STAT3, AKT, ERK, S6K, and JNK proteins was of varying NOTE. Normal human B-lymphocytes isolated from spleen were purified by Ficoll-Hypaque gradient and cultured in complete medium with 5 Ag/mL pokeweed mitogen for 2 hours. B-cells were then treated with vehicle (ethanol) or with 5 or 10 Amol/L 4-OHT for 48 hours, then analyzed with the cytofluorometer after propidium iodide staining (see legend of Fig. 1 ). (Fig. 4B) .
At 100 Amol/L both compounds had an inhibitory effect on cell viability (Fig. 4B) . Neither synergy nor potentiation was evident when SB 203580 (10 or 50 Amol/L) and 4-OHT (5 Amol/L) were added together (Fig. 4C) . These data indicate that the effects of 4-OHT on multiple myeloma are not mediated through changes in survival signaling pathway activities.
Up-Regulation of p27 Kip1 and Down-Regulation of cMyc Are Associated with a Block of Cell Proliferation. The effects of 4-OHT on G 1 arrest prompted us to investigate the expression of cell cycle regulators involved in progression within the G 1 phase progression and the G 1 -to-S transition. As previously reported (15) , NCI-H929 and RPMI 8226 express high to moderate levels of cyclin D1 whereas LP-1 does not. 4-OHT treatment did not affect cyclin D1, cyclin D2, or cyclin D3 levels in all multiple myeloma cells (data not shown). In addition, we analyzed the expression of two cell cycle inhibitors, p21
Cip1 and p27 Kip1 . Importantly, p27 Kip1 , expressed at various basal levels, was up-regulated in a dose-dependent fashion after 4-OHT treatment in NCI-H929, RPMI 8226, and LP-1 cells 6 -low and DiOC 6 -high cells were evaluated within the propidium iodide -negative population of living cells. C, caspase-9 activity assay. Exponentially growing cells were cultured with 10 Amol/L 4-OHT (+) or with vehicle (À) for 48 hours, then cells were harvested. Whole cell lysates were prepared, quantified, and 300 Ag of total proteins were incubated in triplicate in a colorimetric assay with LEHD-pNA as substrate for 2 hours at 37jC. The absorbance of the samples was read at 405 nm. Indicated values represented the specific absorbance minus the absorbance of background. (Fig. 5A) . Down-regulation of c-Myc also occurred when breast cancer cells were treated with pure antiestrogens (19) , a phenomenon also observed in NCI-H929, RPMI 8226, U266, and LP-1 cells after SERM treatment (Fig. 5B) . Our data suggest that p27
Kip1 and c-Myc are essential mediators of cell cycle blockade in G 1 phase following 4-OHT treatment.
Up-Regulation of BimS and Down-Regulation of Mcl-1 Are Both Associated with Antiestrogen-Induced Apoptosis. We also addressed the issue of whether some members of the Bcl-2 family were implicated in 4-OHT-induced apoptosis. The expression of Bcl-2, Bcl-XL, and Bax was unaffected by antiestrogen treatment (17) . However, we observed an induction of the short form of Bim (BimS) The inhibition of cell proliferation in multiple myeloma cells treated with 4-OHT is manifest at micromolar concentrations (>1 Amol/L) but these are much lower than the concentrations of tamoxifen used in previous studies (50-100 Amol/L; refs. 4, 5) . This probably reflects the known higher affinity of 4-OHT for ER (7) . At physiologic concentrations (1, 10, and 100 nmol/L), E2 had no effects on multiple myeloma cell proliferation block or apoptosis (data not shown). By contrast, in breast cancer cells, the effects on cell cycle proteins and cell proliferation are obtained with nanomolar concentrations of these compounds. This work and that of others (4, 5) suggest that a nonclassic genomic action of ER is triggered by SERMs in multiple myeloma cells. Whether a (20, 21) or an unexpected action of 4-OHT/ ER is possible, it has been proposed that the antiestrogen binding sites could be responsible for the growth inhibition of multiple myeloma cells (4) . Antiestrogen binding sites could mediate the binding and in turn the inhibitory effects of 4-OHT in human cancer cells. In multiple myeloma cells, 4-OHT-like effects on cell proliferation were observed also with micromolar concentrations of the pure antiestrogens ICI 182780 or RU 58668. 4 However, 4-OHT was always described as a highaffinity ligand for both ER and antiestrogen binding sites (22, 23) whereas pure antiestrogens have no affinity for antiestrogen binding sites (24) and high affinity for ER (see ref. 7 for a review). Indeed, antiestrogen binding sites result from the association between two enzymes involved in the synthesis of cholesterol precursors (the 3h-hydroxysterol-D8-D7-isomerase and the 3h-hydroxysterol-D7-reductase) without affinity for pure antiestrogens (24) . Therefore, it is unlikely that a mechanism involving antiestrogen binding sites could be responsible for the antiproliferative action of 4-OHT. It is obvious that further clarification is required to explain the activity of SERMs in multiple myeloma cells. Although the mechanism is not full defined, these effects seem dependent on the presence of ER.
The most relevant function for estrogens in breast cancers is the promotion of cell proliferation through cyclin D1 gene (CCND1) activation. Therefore, it is not surprising that in those cells, SERM-mediated cell cycle arrest is associated with the decrease of cyclin D1 gene expression (25, 26) . U266, RPMI 8226, and NCI-H929 cells constitutively express cyclin D1 although at various levels whereas in the LP-1 cell line, the CCND1 gene encoding cyclin D1 is transcriptionally silent (15) . This indicates that in multiple myeloma cells, CCND1 is not the key target of 4-OHT. It has to be noticed that normal breast epithelial cells express physiologically cyclin D1 whereas CCND1 expression in B-lymphocytes is restricted to tumor cells including multiple myeloma cells. The cell cycle p27 Kip1 inhibitor is also an essential mediator of antiestrogen-induced cell cycle arrest in breast cancer (19) . p27
Kip1 is expressed in NCI-H929, LP-1, and RPMI 8226 cells and is up-regulated after SERM treatment. Whereas the pRb pathway is defective in multiple myeloma cells, p27 kip1 is a target of 4-OHT and the accumulation of p27 kip1 is likely responsible for the G 1 arrest observed in multiple myeloma cells. p27
Kip1 is a major regulator of proliferation in most cells, its inhibitory activity being mediated by its binding to cyclin E/Cdk2 complexes (27) . Our preliminary data indicate that in 4-OHT-treated cells inhibition of cyclin E/CDK2 enzymatic activity is achieved through the down-regulation of CDK2. The other major event associated with antiestrogen-mediated G 1 arrest in breast cancer cells is the 4 Unpublished data. acute down-regulation of c-Myc (28). Although probably controlled by different pathway (here this is a late event), the down-regulation of c-myc is also associated with 4-OHTinduced cell cycle blockade in multiple myeloma cells.
Bcl-2, Bcl-XL, and Bax proteins are expressed in multiple myeloma cells; their levels were unchanged after 4-OHT treatment (17) , in good agreement with studies in breast cancer cells in which Bcl-2, Bcl-XL and Bax showed only marginal changes in the presence of antiestrogen (29) . But interestingly, Mcl-1, essential for the survival of multiple myeloma cells (30 -32) , is down-regulated after 4-OHT treatment. The prosurvival role of Mcl-1 is required for the development and the maintenance of B-lymphocytes and its down-regulation has been previously reported in apoptotic multiple myeloma cells treated with flavopyridol (33) . These data indicate that Mcl-1 is an important target of antitumoral compounds in multiple myeloma cells. The BH3-only proapoptotic proteins BimEL, BimL, and BimS are generated by alternative splicing. Unlike BimEL and BimL, which are present in normal cells but inactivated by their interactions with the cytoskeleton, BimS is transiently expressed in apoptotic cells (34) . In good agreement with that, we found an up-regulation of BimS in cells treated with 10 Amol/L antiestrogen (i.e., in apoptotic cells). We have shown here that 4-OHT is able to induce apoptosis through the mitochondrial intrinsic pathway. Our results are consistent with the data in the literature showing that tamoxifen and 4-OHT induce a mitochondrial-and caspase-dependent apoptosis in breast cancer cell lines and primary tumors (10). 4-OHT also triggers apoptosis of ER-transfected HeLa cells through a similar process. Our results are also consistent with literature concerning the mechanism of apoptosis induction in multiple myeloma. Therapeutic drugs such as dexamethasone and 2-methoxyestradiol induce apoptotic cell death, which is mediated through the dissipation of mitochondrial membrane potential. This phenomenon is accompanied by the cytosolic release of various mitochondrial proteins as cytochrome c or Smac/DIABLO (36, 37). Analysis of the subcellular distribution of these mitochondrial proteins has to be envisaged to complete the elucidation of the mechanisms of 4-OHT-induced apoptosis in multiple myeloma cells.
Cross-talks between the ER and phosphatidylinositol 3-kinase, STAT3, or ERKs have been described in various cell types (38) . In breast cancer cells and in ER-transfected HeLa cells, induction of apoptosis is related to the activation of p38 MAPK and JNK survival pathway members (10, 11) . However, our data indicate that the apoptosis induced by 4-OHT in multiple myeloma cells is probably not mediated through activation of these proteins. Our data show that 4-OHT does not dramatically nor significantly affect activation of these signaling pathways, all constitutively activated in multiple myeloma cells. However, it remains possible that 4-OHT inhibits the transcriptional activities of STAT3 and/or other transcription factors acting downstream the phosphatidylinositol 3-kinase or the MAPK pathways. This inhibitory mechanism is now under investigation.
The 4-OHT-mediated apoptosis does not proceed through the activation the extrinsic death pathway. In leukemic cells, the Fas/FasL death pathway seems to be involved in drug-induced cell death but conflicting results have been reported (39, 40) . Interestingly, in myeloma cells, Landowski et al. (41) reported that Fas and chemotherapeutic drugs (anthracens, doxorubicin, and mitoxantrone) trigger independent mechanisms to activate downstream caspases. Our findings are in good agreement with this suggestion.
The induction of apoptosis is required for a chemotherapeutic agent to be active. In that respect, apoptotic cell death can be obtained by the treatment of multiple myeloma cells with 4-OHT. Importantly, in the same experimental conditions, normal B-lymphocytes are not affected by the antiestrogen treatment. Moreover, the apoptosis-inducing effect of 4-OHT is not mediated through inhibition of survival pathways associated with growth of multiple myeloma cells. Because bone marrow environment confers resistance to drug treatment through the activation of such survival pathways (2), the use of 4-OHT, which targets exclusively the intrinsic death pathway, is of major interest. Interestingly, induction of multiple myeloma apoptosis is obtained with 4-OHT concentrations (5-10 Amol/L) already evaluated clinically and compatible with anticancer treatment (42) . Moreover, although our experiments must be repeated in the future with primary myeloma cells, we are confident that 4-OHT does not exert its antiproliferative and proapoptotic effects on S phase. Thus, myeloma cells, which possess a low labeling index with less than 0.5% of cells in S phase, could be the target of 4-OHT. Finally, the effects of 4-OHT are observed on cell lines exhibiting various degrees of resistance to chemotherapeutic agents. RPMI 8226, NCI-H929, and U266 are resistant to glucocorticoids and/or DNA-damaging agents (see for example refs. 43, 44) . Resistance towards conventional anticancer drugs frequently appears de novo during the treatment of multiple myeloma disease. Combined association of 4-OHT with conventional drugs could potentially overcome such resistance.
